|Other names||Lu AA24530; Lu-AA-24530|
|Chemical and physical data|
|Molar mass||283.43 g·mol−1|
|3D model (JSmol)|
|NY (what is this?)|
Tedatioxetine (Lu AA24530) is an antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.
As of 2009, it was in phase II clinical trials for major depressive disorder, but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.
On May 10, 2016, all work on tedatioxetine stopped.
A Sino Patent manages to show that there has been interest in this compound outside of Lundbeck: WO 2015090160
- Beaulieu D (5 September 2007). "Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs]". First Word Pharma.
- US 2010144788, Stensbol TB, Miller S, "4-[2-(4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression", published 10 June 2010, assigned to H Lundbeck AS
- Stahl SM (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011.
- Stolerman IP (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011.
- "Lu AA24530 shows positive results in major depressive disorder phase II study". FierceBiotech. 2 July 2009.
- "Pipeline of Lundbeck". Retrieved 25 August 2013.
- "Tedatioxetine". UK Medicines Information. Retrieved 20 January 2016.
- "Tedatioxetine". AdisInsight. Springer Nature Switzerland AG. Retrieved 2016-06-09.